Eastwood Bio-Medical Canada (EBM) AI Stock Analysis

• Market Cap: C$37.89M
• Dividend Yield: N/A
• Average Volume (3M): 3.49K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: -9.02%
• EPS Growth: 14.29%
• Country: CA
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Food Distribution
• EPS (TTM): N/A
• Shares Outstanding: 68,885,970
• 10 Day Avg. Volume: 3,055
• 30 Day Avg. Volume: 3,488
• PEG Ratio: 5.31
• Price to Book (P/B): -29.59
• Price to Sales (P/S): 61.66
• P/FCF Ratio: 2.50K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.53 ▼(-34.00% Downside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is held down primarily by persistent losses and deeply negative equity, which outweigh the improving 2025 revenue and cash-flow stabilization. Technically, the stock shows weak trend/momentum (below key moving averages with negative MACD), and valuation support is limited given the negative P/E and no provided dividend yield.

Positive Factors

Improving cash generation

Operating and free cash flow turning positive in 2025 signals a structural improvement in working-capital management and cost control. Sustained positive cash generation over months supports liquidity, reduces near-term financing reliance, and provides a platform for reinvestment if maintained.

Revenue rebound in 2025

A clear revenue rebound in 2025 indicates recovering demand or improved execution in the company's Food Distribution business. Durable top-line growth helps absorb fixed costs, improves operating leverage potential, and gives management scope to drive margin improvement toward sustainable profitability.

Stable, relatively high gross margins

Relatively high and stable gross margins in 2024–2025 point to structural pricing power or favorable product mix in distribution. Stable gross margins create a durable buffer that can support recovery to profit as revenues scale, making long-term margin sustainability more achievable.

Negative Factors

Persistent operating and net losses

Recurring operating and net losses across all reported years are a structural drain on capital and limit the firm's ability to self-fund growth. Continued negative profitability raises the probability of incremental financing needs and constrains strategic flexibility over the medium term.

Negative stockholders' equity

A large accumulated deficit and negative equity from 2021–2025 materially weaken the balance sheet, increasing refinancing and going-concern risk. This structural impairment limits access to capital, raises borrowing costs, and constrains investment or M&A options absent recapitalization.

Fragile recovery / weak free cash flow scale

Although cash flow turned positive, free cash flow declined versus 2024 and remains small relative to ongoing losses. This suggests the recovery could be fragile and sensitive to working-capital swings; a reversal would quickly pressure liquidity and force external funding.

Eastwood Bio-Medical Canada Business Overview & Revenue Model

Company Description

Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones, teeth, and good health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its products also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada.

How the Company Makes Money

null

Eastwood Bio-Medical Canada Financial Statement Overview

Summary

Despite a strong 2025 revenue rebound and improved cash generation (operating and free cash flow positive in 2025), the company remains structurally weak: persistent operating and net losses across all years shown and negative stockholders’ equity from 2021–2025 materially elevate financial risk.

Income Statement

Revenue has been volatile but improved in the latest year (2025 revenue up strongly versus 2024), and gross margin is relatively stable and high in 2024–2025. However, profitability remains a major issue: the company has posted net losses every year shown, with operating losses also persistent. While margins improved materially from the extremely weak 2020 level, 2025 still shows a large negative net margin, indicating the business has not yet converted its revenue recovery into sustainable earnings.

Balance Sheet

The balance sheet is pressured by a large accumulated deficit, with stockholders’ equity negative from 2021 through 2025, which materially weakens financial flexibility and increases refinancing/going-concern risk. Reported debt levels are not large in absolute terms, but leverage measures are distorted by negative equity and do not indicate true balance-sheet strength. Total assets have also trended down versus earlier years, reinforcing the constrained capital position despite some improvement from the 2020 profitability trough.

Cash Flow

Cash generation has improved meaningfully versus earlier years: operating cash flow and free cash flow turned positive in 2025 after multiple years of negative readings, suggesting better working-capital and/or cost control. That said, cash flow remains small relative to the scale of losses (profitability is still negative), and free cash flow declined versus 2024, highlighting that the recovery is early and may be fragile.

Breakdown	Oct 2025	Jan 2025	Oct 2023	Oct 2022	Jan 2022
Income Statement
Total Revenue	782.08K	702.08K	867.94K	1.30M	981.05K
Gross Profit	506.03K	454.39K	440.51K	902.74K	458.37K
EBITDA	-309.73K	-342.05K	-410.58K	-32.33K	-495.50K
Net Income	-332.77K	-455.87K	-546.60K	-160.58K	-611.34K
Balance Sheet
Total Assets	218.77K	274.29K	489.14K	584.53K	691.12K
Cash, Cash Equivalents and Short-Term Investments	17.70K	0.00	18.45K	39.84K	20.87K
Total Debt	78.01K	79.61K	23.08K	62.25K	31.35K
Total Liabilities	1.85M	1.57M	1.33M	878.73K	835.44K
Stockholders Equity	-1.63M	-1.30M	-840.80K	-294.20K	-144.32K
Cash Flow
Free Cash Flow	19.30K	-15.22K	-16.89K	-7.30K	-121.79K
Operating Cash Flow	19.30K	-15.22K	-16.89K	-4.29K	-116.21K
Investing Cash Flow	0.00	0.00	0.00	-3.00K	-5.57K
Financing Cash Flow	-211.00	-4.62K	-4.50K	26.27K	20.00K

Eastwood Bio-Medical Canada Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Negative. The current price of 0.8 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.71, and above the 200-day MA of 0.60, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.47 is Neutral, neither overbought nor oversold. The STOCH value of 37.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:EBM.

Eastwood Bio-Medical Canada Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
ATLE	50 Neutral	C$52.83M	-2.62	-19.76%	―	26.91%	81.01%
ADK	45 Neutral	C$31.91M	-9.48	3086.87%	―	-48.53%	-9.66%
EBM	42 Neutral	C$37.89M	-144.91	―	―	-9.02%	14.29%
SONA	42 Neutral	C$37.17M	-21.43	-434.25%	―	―	10.97%
ARCH	41 Neutral	C$38.15M	-12.93	72.34%	―	―	10.49%